newsfilter
← Latest News
GlobeNewswire·

CymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th Fifth oral late-breaking presentation of seladelpar results at The Liver Meeting® NEWARK, Calif.,